Tiziana Life Sciences annual stock-based compensation
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Tiziana Life Sciences Stock-Based Compensation Growth & History (TLSA)
Tiziana Life Sciences's stock-based compensation was $1.1M for fiscal 2025.
View full Tiziana Life Sciences company overviewTiziana Life Sciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.1M | −$1.2M | −51.20% |
| 2024 | 2024-12-31 | $2.3M | $608,000 | +35.14% |
| 2023 | 2023-12-31 | $1.7M | $320,000 | +22.70% |
| 2022 | 2022-12-31 | $1.4M | −$3.8M | −72.74% |
| 2021 | 2021-12-31 | $5.2M | $68,000 | +1.33% |
| 2020 | 2020-12-31 | $5.1M | $3.8M | +303.24% |
| 2019 | 2019-12-31 | $1.3M | $727,000 | +134.88% |
| 2018 | 2018-12-31 | $539,000 | $0 | 0.00% |
| 2017 | 2017-12-31 | $539,000 | −$476,000 | −46.90% |
| 2016 | 2016-12-31 | $1.0M | — | — |
Tiziana Life Sciences stock-based compensation trends
Over the last five fiscal years, Tiziana Life Sciences's stock-based compensation decreased from $5.1M to $1.1M, a change of −$4.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tiziana Life Sciences source filings ↗